A Study Evaluating Tocilizumab in Pediatric Patients Hospitalized With COVID-19

Inclusion Criteria: * Hospitalized with COVID-19 confirmed per a positive PCR of any specimen (e.g., respiratory, blood, urine, stool, or other bodily fluid) and evidenced by chest x-ray or CT scan * Receiving systemic corticosteroids at baseline * Oxygen saturation \< 93% on room air, or requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) to maintain oxygen saturation \> 92% at screening and baseline Exclusion Criteria: * Gestational age \< 37 weeks * Known severe allergic reactions to TCZ or other monoclonal antibodies * Active tuberculosis infection * Uncontrolled active bacterial, fungal, viral, or other infection (besides COVID-19) * Diagnosis or suspected diagnosis of multisystem inflammatory syndrome in children (MIS-C) * In the opinion of the investigator, progression to death is imminent and inevitable within the next 48 hours, irrespective of the provision of treatments * Have received oral anti-rejection or immunomodulatory drugs (including TCZ) within the past 3 months prior to enrollment * Treatment with an investigational drug within 5 drug-elimination half-lives or 30 days, whichever is longer, of enrollment (except for anti-SARS-CoV-2 antibodies or directly-acting antivirals) * Participating in another interventional drug clinical trial (except for anti-SARS-CoV-2 antibodies or directly-acting antivirals)